Medicamento para la artritis reduce muertes por COVID

Un estudio realizado en Reino Unido, demostró que el fármaco para la artritis reumatoide baricitinib también reduce el riesgo de muerte por SARS-CoV-2.

[{"selector":"#anim-2f3b483a-7326-42ea-89cf-e2977db21a42","keyframes":{"opacity":[0,1]},"delay":0,"duration":600,"easing":"cubic-bezier(0.2, 0.6, 0.0, 1)","fill":"both"}] [{"selector":"#anim-abc72af7-5d5a-4f11-b549-01f99df7a746","keyframes":{"transform":["translate3d(114.55696%, 0px, 0)","translate3d(0px, 0px, 0)"]},"delay":0,"duration":600,"easing":"cubic-bezier(0.2, 0.6, 0.0, 1)","fill":"both"}]

El trabajo, denominado Recovery, indicaría que los medicamentos que combaten la inflamación pueden ayudar a los pacientes infectados con el virus.

[{"selector":"#anim-f4b0e454-a74f-4fbd-82a5-3d8e9586288f","keyframes":{"opacity":[0,1]},"delay":0,"duration":600,"easing":"cubic-bezier(0.2, 0.6, 0.0, 1)","fill":"both"}] [{"selector":"#anim-7e0a37cf-7fb8-45d2-9de4-34de21e7db17","keyframes":{"transform":["translate3d(0px, -425.97495%, 0)","translate3d(0px, 0px, 0)"]},"delay":0,"duration":600,"easing":"cubic-bezier(0.2, 0.6, 0.0, 1)","fill":"both"}]

Los resultados del ensayo realizado en 8.156 personas con la enfermedad, mostraron que el baricitinib en tratamientos estándar redujo en un 13% el riesgo de muerte en pacientes hospitalizados con COVID.

[{"selector":"#anim-11831915-6f50-47c8-9349-44c2600f7ff2","keyframes":{"opacity":[0,1]},"delay":0,"duration":600,"easing":"cubic-bezier(0.2, 0.6, 0.0, 1)","fill":"both"}] [{"selector":"#anim-170ee37e-ee4f-4d2a-8d79-6e35dbc2a586","keyframes":{"transform":["translate3d(114.19355%, 0px, 0)","translate3d(0px, 0px, 0)"]},"delay":0,"duration":600,"easing":"cubic-bezier(0.2, 0.6, 0.0, 1)","fill":"both"}]

Las terapias reducen las reacciones inmunitarias potencialmente letales al bloquear un mensaje celular para producir factores que combaten las infecciones.

[{"selector":"#anim-2f478363-2e93-4e13-9874-fdf6e430fb3b","keyframes":{"transform":["translate3d(-123.52942%, 0px, 0)","translate3d(0px, 0px, 0)"]},"delay":0,"duration":600,"easing":"cubic-bezier(0.4, 0.4, 0.0, 1)","fill":"both"}] [{"selector":"#anim-c2ed564a-256d-45ce-9c94-db6ac4abcbb1","keyframes":{"opacity":[0,1]},"delay":0,"duration":600,"easing":"cubic-bezier(0.4, 0.4, 0.0, 1)","fill":"both"}] [{"selector":"#anim-0cf0ca4e-8020-419e-ade6-6f4e761059c0","keyframes":{"transform":["scale(0.15)","scale(1)"]},"delay":0,"duration":600,"easing":"cubic-bezier(0.4, 0.4, 0.0, 1)","fill":"forwards"}]

Ya en enero, la Organización Mundial de la Salud había recomendado baricitinib en pacientes con COVID grave. Además, podría usarse junto a otros tratamientos para salvar más vidas.

[{"selector":"#anim-d7c34ff5-ee83-479e-bbb9-bdfaf96c935c","keyframes":{"opacity":[0,1]},"delay":0,"duration":600,"easing":"cubic-bezier(0.2, 0.6, 0.0, 1)","fill":"both"}] [{"selector":"#anim-6eadf74d-c2e8-42b6-912b-d237e72ab898","keyframes":{"transform":["translate3d(0px, -358.98415%, 0)","translate3d(0px, 0px, 0)"]},"delay":0,"duration":600,"easing":"cubic-bezier(0.2, 0.6, 0.0, 1)","fill":"both"}]

“Se abre la posibilidad de usar combinaciones de medicamentos antiinflamatorios para reducir aún más el riesgo de muerte”, dijo Martin Landray, jefe conjunto del ensayo.

[{"selector":"#anim-10ba47aa-ada8-4d68-ba7e-b344041c85a2","keyframes":{"opacity":[0,1]},"delay":300,"duration":600,"easing":"cubic-bezier(0.2, 0.6, 0.0, 1)","fill":"both"}] [{"selector":"#anim-f0313f20-b376-4944-8c5a-54d37510a662","keyframes":{"transform":["translate3d(0px, -139.01611%, 0)","translate3d(0px, 0px, 0)"]},"delay":300,"duration":600,"easing":"cubic-bezier(0.2, 0.6, 0.0, 1)","fill":"both"}]

[{"selector":"#anim-95a1a0aa-e26c-468b-9966-d0bc8c56efbe","keyframes":{"opacity":[0,1]},"delay":500,"duration":1000,"easing":"cubic-bezier(0.2, 0.6, 0.0, 1)","fill":"both"}] [{"selector":"#anim-fdcbe250-1c09-4e77-ab1d-bf2e649315a5","keyframes":{"transform":["translate3d(0px, 889.30081%, 0)","translate3d(0px, 0px, 0)"]},"delay":500,"duration":1000,"easing":"cubic-bezier(0.2, 0.6, 0.0, 1)","fill":"both"}] [{"selector":"#anim-53581e43-8e0b-411b-8024-6c3ca3548144","keyframes":{"opacity":[0,1]},"delay":500,"duration":1000,"easing":"cubic-bezier(0.2, 0.6, 0.0, 1)","fill":"both"}] [{"selector":"#anim-dc8d314a-9a84-47be-abc8-a2c7f46653f0","keyframes":{"transform":["translate3d(0px, 1168.55761%, 0)","translate3d(0px, 0px, 0)"]},"delay":500,"duration":1000,"easing":"cubic-bezier(0.2, 0.6, 0.0, 1)","fill":"both"}] [{"selector":"#anim-6191da38-0c0d-4f67-b3e9-8c58f8eaa727","keyframes":{"opacity":[0,1]},"delay":500,"duration":1000,"easing":"cubic-bezier(0.2, 0.6, 0.0, 1)","fill":"both"}] [{"selector":"#anim-0c2c600b-b032-4201-b11e-e72957d53dfd","keyframes":{"transform":["translate3d(0px, 819.51565%, 0)","translate3d(0px, 0px, 0)"]},"delay":500,"duration":1000,"easing":"cubic-bezier(0.2, 0.6, 0.0, 1)","fill":"both"}] [{"selector":"#anim-51cb2fee-ec97-4000-83cf-a542aef06aff [data-leaf-element=\"true\"]","keyframes":{"transform":["translate3d(31.246337776828504%, 0, 0) translate(25%, 0%) scale(1.5)","translate3d(0%, 0, 0) translate(0%, 0%) scale(1)"]},"delay":0,"duration":2000,"easing":"cubic-bezier(.14,.34,.47,.9)","fill":"forwards"}]